221 related articles for article (PubMed ID: 31698452)
1. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
2. Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.
Wong KY; Yao Q; Yuan LQ; Li Z; Ma ESK; Chim CS
Sci Rep; 2018 Sep; 8(1):13522. PubMed ID: 30201956
[TBL] [Abstract][Full Text] [Related]
3. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Müller E; Bauer S; Stühmer T; Mottok A; Scholz CJ; Steinbrunn T; Brünnert D; Brandl A; Schraud H; Kreßmann S; Beilhack A; Rosenwald A; Bargou RC; Chatterjee M
Leukemia; 2017 Apr; 31(4):922-933. PubMed ID: 27686868
[TBL] [Abstract][Full Text] [Related]
4. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
Li S; Fu J; Yang J; Ma H; Bhutani D; Mapara MY; Marcireau C; Lentzsch S
Blood; 2021 Apr; 137(13):1754-1764. PubMed ID: 33036022
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N; Martínez-Trillos A; Montraveta A; Lopez-Guerra M; Rosich L; Nadeu F; Valero JG; Aymerich M; Magnano L; Rozman M; Matutes E; Delgado J; Baumann T; Gine E; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer AR; Puente XS; López-Otín C; Lopez-Guillermo A; Campo E; Colomer D; Villamor N
Haematologica; 2019 Mar; 104(3):576-586. PubMed ID: 30262568
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
7. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
9. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Way GP; Sanchez-Vega F; La K; Armenia J; Chatila WK; Luna A; Sander C; Cherniack AD; Mina M; Ciriello G; Schultz N; ; Sanchez Y; Greene CS
Cell Rep; 2018 Apr; 23(1):172-180.e3. PubMed ID: 29617658
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
[TBL] [Abstract][Full Text] [Related]
11. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
[TBL] [Abstract][Full Text] [Related]
13. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.
Steinbrunn T; Stühmer T; Gattenlöhner S; Rosenwald A; Mottok A; Unzicker C; Einsele H; Chatterjee M; Bargou RC
Blood; 2011 Feb; 117(6):1998-2004. PubMed ID: 21149634
[TBL] [Abstract][Full Text] [Related]
14. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
15. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
17. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
18. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
Masih-Khan E; Trudel S; Heise C; Li Z; Paterson J; Nadeem V; Wei E; Roodman D; Claudio JO; Bergsagel PL; Stewart AK
Blood; 2006 Nov; 108(10):3465-71. PubMed ID: 16849642
[TBL] [Abstract][Full Text] [Related]
19. Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.
Zhu FX; He YC; Zhang JY; Wang HF; Zhong C; Wang XT
Med Sci Monit; 2019 May; 25():3247-3255. PubMed ID: 31048671
[TBL] [Abstract][Full Text] [Related]
20. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]